IRulya Therapeutics Inc. (IRLA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IRLA SEC filings page.
This page shows IRulya Therapeutics Inc. (IRLA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
IRulya Therapeutics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
IRulya Therapeutics Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
IRulya Therapeutics Inc. reported a net loss of $84.0M while operations used $41.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
IRulya Therapeutics Inc.'s EBITDA was -$79.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 667.3% from the same quarter a year earlier. Against the prior quarter it is down 447.9%.
IRulya Therapeutics Inc. reported -$75.5M in net income in Q2 2026. This represents a decrease of 370.4% from the same quarter a year earlier. Against the prior quarter it is down 310.2%.
Not reported for Q2 2026.
Cash & Balance Sheet
IRulya Therapeutics Inc. recorded an outflow of $18.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 63.7% from the same quarter a year earlier. Against the prior quarter it is down 147.6%.
IRulya Therapeutics Inc. held $116.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
IRulya Therapeutics Inc. invested $5.5M in research and development in Q2 2026. This represents a decrease of 16.7% from the same quarter a year earlier. Against the prior quarter it is down 20.2%.
IRulya Therapeutics Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
IRLA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $5.5M-16.7% | $6.8M-16.0% | N/A | $8.1M+64.4% | $6.6M+58.0% | $8.1M+120.0% | N/A | $4.9M+243.5% |
| SG&A Expenses | $16.6M+397.5% | $4.3M-10.9% | N/A | $3.3M-9.6% | $3.3M-28.8% | $4.8M-3.7% | N/A | $3.6M-22.2% |
| Operating Income | -$79.8M-665.1% | -$14.6M+1.8% | N/A | -$13.4M-129.1% | -$10.4M+63.0% | -$14.9M-32.4% | N/A | -$5.9M+3.8% |
| EBITDA | -$79.7M-667.3% | -$14.6M+1.8% | N/A | -$13.4M-131.9% | -$10.4M+63.1% | -$14.8M-32.6% | N/A | -$5.8M+5.2% |
| Income Tax | $75K+11.9% | -$5.3M-11459.6% | N/A | -$46K-453.8% | $67K+86.1% | $47K+51.6% | N/A | $13K |
| Net Income | -$75.5M-370.4% | $35.9M+338.9% | N/A | -$13.4M-144.8% | -$16.0M+42.1% | -$15.0M-34.8% | N/A | -$5.5M-2.6% |
| EPS (Basic) | -$12.31+82.1% | $3.60+205.3% | -$0.76-171.4% | -$0.25-92.3% | -$68.75-10642.2% | -$3.42-1215.4% | -$0.28-33.3% | -$0.13+13.3% |
| EPS (Diluted) | -$12.31 | $2.88 | -$0.76 | -$0.25-92.3% | -$68.75 | -$3.42 | -$0.28-33.3% | -$0.13+13.3% |
| Diluted Shares (Avg) | 6M | 9M | N/A | 54M+25.0% | 233,431 | 4M | N/A | 43M+19.7% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
IRLA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $124.0M+5.8% | $26.6M-75.1% | $93.5M-18.3% | $109.9M-13.1% | $117.2M-13.1% | $107.1M-32.8% | $114.5M-31.8% | $126.5M+48.2% |
| Current Assets | $123.4M+230.5% | $25.6M-24.4% | $22.9M-48.0% | $29.2M-43.5% | $37.3M-41.1% | $33.8M-52.0% | $44.0M-43.1% | $51.7M-39.3% |
| Cash & Equivalents | $116.0M+589.3% | $18.2M+133.7% | $5.8M-6.5% | $6.5M+141.2% | $16.8M+113.3% | $7.8M-64.4% | $6.2M-70.1% | $2.7M-87.2% |
| Short-Term Investments | $0-100.0% | $0-100.0% | $11.9M-65.5% | $19.8M-56.1% | $17.9M-65.3% | $23.8M-48.2% | $34.6M-36.3% | $45.2M-26.7% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | $0 | N/A | N/A | $0-100.0% | $0 |
| Total Liabilities | $159.3M+51.1% | $11.0M-87.6% | $129.2M+53.2% | $108.8M+33.4% | $105.5M+20.0% | $88.5M+4.0% | $84.3M+1.8% | $81.6M+3521.3% |
| Current Liabilities | $8.5M+13.8% | $8.8M+4.9% | $43.2M+493.9% | $26.0M+380.1% | $7.5M-27.7% | $8.4M-15.1% | $7.3M-24.0% | $5.4M+140.8% |
| Non-Current Liabilities | $150.8M+53.9% | $2.2M-97.3% | $86.0M+11.6% | $82.8M+8.7% | $98.0M+26.4% | $80.2M+6.5% | $77.1M+5.2% | $76.2M |
| Long-Term Debt | N/A | N/A | $0-100.0% | $0-100.0% | $17.0M+22.8% | $15.3M+12.9% | $14.3M+6.6% | $14.9M |
| Total Equity | -$35.3M-401.0% | $15.7M-15.7% | -$35.7M-218.5% | $1.1M-97.6% | $11.7M-75.0% | $18.6M-75.0% | $30.1M-64.6% | $44.9M-46.0% |
| Retained Earnings | -$500.0M-22.7% | -$424.5M-8.4% | -$460.5M-22.3% | -$421.0M-15.7% | -$407.6M-13.7% | -$391.5M-18.4% | -$376.5M-17.8% | -$364.0M-17.1% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
IRLA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.9M-65.5% | -$7.6M+20.6% | -$10.5M-38.8% | -$9.9M-36.7% | -$11.4M-30.6% | -$9.6M-14.9% | -$7.6M-24.3% | -$7.3M-50.7% |
| Depreciation & Amortization | $41K+17.1% | $36K+12.5% | $39K+143.8% | $36K-58.1% | $35K-20.5% | $32K-20.0% | $16K-94.7% | $86K |
| Stock-Based Compensation | $12.1M+850.0% | $1.3M-7.2% | N/A | $1.3M+11.7% | $1.3M+4.1% | $1.4M+8.8% | N/A | $1.1M-15.6% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $4K-97.0% | $74K+60.9% | $126K+223.1% | $148K+279.5% | $133K+454.2% | $46K |
| Free Cash Flow | -$18.9M-63.7% | -$7.6M+21.8% | -$10.5M-36.4% | -$10.0M-36.9% | -$11.5M-31.5% | -$9.7M-16.2% | -$7.7M-25.9% | -$7.3M-51.6% |
| Investing Cash Flow | $8.0M+32.5% | $12.0M+10.1% | $8.1M-25.7% | -$1.8M-125.1% | $6.0M+221.3% | $10.9M+22.3% | $10.9M+101.6% | $7.1M+95.5% |
| Financing Cash Flow | $108.9M+655.8% | $9.4M+10754.0% | $2.0M | $1.4M+127.5% | $14.4M+41077.1% | $87K-54.2% | $0-100.0% | -$5.0M-50100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IRLA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | 229.2%+310.0pp | N/A | -1269.3%-1257.1pp | -136.8%-77.7pp | -80.9%-65.9pp | N/A | -12.2%-5.8pp |
| Return on Assets | -60.9%-47.2pp | 134.9%+148.9pp | N/A | -12.2%-7.9pp | -13.7%+6.9pp | -14.0%-7.0pp | N/A | -4.3%+1.9pp |
| Current Ratio | 14.52+9.5x | 2.92-1.1x | 0.53-5.5x | 1.12-8.4x | 5.00-1.1x | 4.05-3.1x | 6.05-2.0x | 9.53-28.3x |
| Debt-to-Equity | N/A | 0.70-0.1x | N/A | 0.00-0.3x | 1.45+1.2x | 0.82+0.6x | 0.48+0.3x | 0.33+0.3x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$35.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.53), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where IRulya Therapeutics Inc. Ranks
Frequently Asked Questions
Is IRulya Therapeutics Inc. profitable?
No, IRulya Therapeutics Inc. (IRLA) reported a net income of -$84.0M in fiscal year 2025.
What is IRulya Therapeutics Inc.'s EBITDA?
IRulya Therapeutics Inc. (IRLA) had EBITDA of -$57.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does IRulya Therapeutics Inc. have?
As of fiscal year 2025, IRulya Therapeutics Inc. (IRLA) had $5.8M in cash and equivalents against $0 in long-term debt.
What is IRulya Therapeutics Inc.'s free cash flow?
IRulya Therapeutics Inc. (IRLA) recorded an outflow of $41.8M in free cash flow during fiscal year 2025. This represents a -29.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is IRulya Therapeutics Inc.'s operating cash flow?
IRulya Therapeutics Inc. (IRLA) recorded an outflow of $41.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are IRulya Therapeutics Inc.'s total assets?
IRulya Therapeutics Inc. (IRLA) had $93.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are IRulya Therapeutics Inc.'s capital expenditures?
IRulya Therapeutics Inc. (IRLA) invested $352K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does IRulya Therapeutics Inc. spend on research and development?
IRulya Therapeutics Inc. (IRLA) invested $35.4M in research and development during fiscal year 2025.
What is IRulya Therapeutics Inc.'s current ratio?
IRulya Therapeutics Inc. (IRLA) had a current ratio of 0.53 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is IRulya Therapeutics Inc.'s return on assets (ROA)?
IRulya Therapeutics Inc. (IRLA) had a return on assets of -89.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is IRulya Therapeutics Inc.'s P/E ratio?
IRulya Therapeutics Inc. (IRLA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $35.3M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is IRulya Therapeutics Inc.'s price-to-sales ratio?
IRulya Therapeutics Inc. (IRLA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $35.3M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does IRulya Therapeutics Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, IRulya Therapeutics Inc. (IRLA) held $17.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $41.4M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is IRulya Therapeutics Inc.'s debt-to-equity ratio negative or not reported?
IRulya Therapeutics Inc. (IRLA) has negative shareholder equity of -$35.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is IRulya Therapeutics Inc.'s Piotroski F-Score?
IRulya Therapeutics Inc. (IRLA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are IRulya Therapeutics Inc.'s earnings high quality?
IRulya Therapeutics Inc. (IRLA) reported a net loss of $84.0M while operations used $41.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.